

Zelda Therapeutics Ltd

13:43 17 May 2019

Zelda Therapeutics on rapid path to medicinal cannabis commercialisation

Zelda Therapeutics Ltd (ASX:ZLD) is on a rapid path to commercialisation of its medicinal cannabis products aimed at treating pain, anxiety, sleep apnea and cancer.

The company's managing director Dr Richard Hopkins told investors at this week's Proactive CEO Sessions in Sydney and Melbourne that the company is well placed to service a rapidly growing global market.

READ: Zelda Therapeutics to use Federal Government R&D tax rebate of \$769,000 to drive clinical trials

He said the company was building a portfolio of clinically validated assets which presented multiple revenue opportunities to license and generate milestone and royalty payments.

This strategy was well advanced because the company had a singular focus on clinical validation to address key unmet needs.

Market dynamics


Among the interesting medicinal cannabis market dynamics outlined were:

- Medicinal cannabis is legal in more than 34 countries and in 35 US states;
- Only around 1% of the population in the US and Canada is registered to use medicinal cannabis;
- The medicinal cannabis market is forecast to grow to \$40-55 billion by 2028 (18% CAGR);
- Around US\$20 billion has been raised by medicinal cannabis companies over the last four years; and
- 21 kilograms is the amount of cannabis required to consume for a lethal dose.

Price: A\$0.066

Market Cap: A\$49.85M

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
A\$0.09 A\$0.03

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelda Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Zelda has a number of upcoming catalysts including results of three first-in-class clinical trials, an insomnia trial, observational autism trial and opioid reduction trial, which are due in the second half of 2019.

Among the recent highlights are an expanded pre-clinical program for cancers and cognitive decline, and a manufacture and German distribution agreement with Hapa Medical BV.

Zelda has also established partnerships with US-based Ilera Healthcare to access more than 110,000 patients and with Suda to develop proprietary oral mucosal formulations.

Read Dr Richard Hopkins presentation.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.